These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
669 related articles for article (PubMed ID: 26514978)
1. Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study. Kovacs KT; Kalluri SR; Boza-Serrano A; Deierborg T; Csepany T; Simo M; Rokusz L; Miseta A; Alcaraz N; Czirjak L; Berki T; Molnar T; Hemmer B; Illes Z Mult Scler; 2016 Aug; 22(9):1192-201. PubMed ID: 26514978 [TBL] [Abstract][Full Text] [Related]
2. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. Mader S; Gredler V; Schanda K; Rostasy K; Dujmovic I; Pfaller K; Lutterotti A; Jarius S; Di Pauli F; Kuenz B; Ehling R; Hegen H; Deisenhammer F; Aboul-Enein F; Storch MK; Koson P; Drulovic J; Kristoferitsch W; Berger T; Reindl M J Neuroinflammation; 2011 Dec; 8():184. PubMed ID: 22204662 [TBL] [Abstract][Full Text] [Related]
3. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690 [TBL] [Abstract][Full Text] [Related]
4. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M; J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675 [TBL] [Abstract][Full Text] [Related]
5. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Rostásy K; Mader S; Hennes EM; Schanda K; Gredler V; Guenther A; Blaschek A; Korenke C; Pritsch M; Pohl D; Maier O; Kuchukhidze G; Brunner-Krainz M; Berger T; Reindl M Mult Scler; 2013 Jul; 19(8):1052-9. PubMed ID: 23257621 [TBL] [Abstract][Full Text] [Related]
6. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068 [TBL] [Abstract][Full Text] [Related]
7. Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. Mader S; Lutterotti A; Di Pauli F; Kuenz B; Schanda K; Aboul-Enein F; Khalil M; Storch MK; Jarius S; Kristoferitsch W; Berger T; Reindl M PLoS One; 2010 May; 5(5):e10455. PubMed ID: 20463974 [TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Jarius S; Franciotta D; Bergamaschi R; Wildemann B; Wandinger KP Clin Chem Lab Med; 2010 May; 48(5):659-63. PubMed ID: 20184532 [TBL] [Abstract][Full Text] [Related]
9. Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up. Piccolo L; Woodhall M; Tackley G; Juryńczyk M; Kong Y; Domingos J; Gore R; Vincent A; Waters P; Leite MI; Palace J J Neurol; 2016 Feb; 263(2):370-379. PubMed ID: 26668077 [TBL] [Abstract][Full Text] [Related]
10. Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. Kim W; Lee JE; Li XF; Kim SH; Han BG; Lee BI; Kim JK; Choi K; Kim HJ Mult Scler; 2012 May; 18(5):578-86. PubMed ID: 21965418 [TBL] [Abstract][Full Text] [Related]
11. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Hinson SR; McKeon A; Fryer JP; Apiwattanakul M; Lennon VA; Pittock SJ Arch Neurol; 2009 Sep; 66(9):1164-7. PubMed ID: 19752309 [TBL] [Abstract][Full Text] [Related]
12. Semiquantitative measurement of aquaporin-4 antibodies as a possible surrogate marker of neuromyelitis optica spectrum disorders with systemic autoimmune diseases. Katsumata Y; Kawachi I; Kawaguchi Y; Gono T; Ichida H; Hara M; Yamanaka H Mod Rheumatol; 2012 Sep; 22(5):676-84. PubMed ID: 22183613 [TBL] [Abstract][Full Text] [Related]
13. Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients. Fazio R; Malosio ML; Lampasona V; De Feo D; Privitera D; Marnetto F; Centonze D; Ghezzi A; Comi G; Furlan R; Martino G Mult Scler; 2009 Oct; 15(10):1153-63. PubMed ID: 19667009 [TBL] [Abstract][Full Text] [Related]
14. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Takahashi T; Fujihara K; Nakashima I; Misu T; Miyazawa I; Nakamura M; Watanabe S; Shiga Y; Kanaoka C; Fujimori J; Sato S; Itoyama Y Brain; 2007 May; 130(Pt 5):1235-43. PubMed ID: 17449477 [TBL] [Abstract][Full Text] [Related]